TriangleOlutasidenib (NCT06668584)
Olutasidenib trial for Myeloid Malignancies (NCT06668584). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults aged eighteen to seventy-five with IDH1-mutated AML, MDS, MPN or CMML in morphologic remission after a first or second donor transplant. Measurable residual disease may be present or absent.
The idea: start oral olutasidenib thirty to one hundred twenty days after transplant, twice daily for up to two years. It blocks mutant IDH1, which may help abnormal cells mature. Researchers assess safety, relapse and survival. Graft-versus-host-disease criteria apply; prior post-transplant maintenance is excluded.
This phase 2 study plans 31 patients. Jeremy Ramdial leads MD Anderson's recruiting Houston site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.